AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04183725 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reduning injection
Description: Reduning injection:~2≤Age≤5,0.5ml/kg/day,\<10ml/day+5％GS/0.9％NS 50～100ml,iv drip 30～40gtt/min qd\*5; 6≤Age≤10,10ml/day+5％GS/0.9％NS 100～200ml,iv drip 30～60gtt/min qd\*5; 11≤Age≤13,15ml/day+5％GS/0.9％NS 200～250ml,iv drip 30～60gtt/min qd\*5; Age=14,20ml/day+5％GS/0.9％NS 250ml,iv drip 30～60gtt/min qd\*5.~Oseltamivir phosphate granules simulants:~Weight≤15kg,30mg,po,bid\*5; 15\<Weight≤23kg,45mg,po,bid\*5; 23\<Weight≤40kg,60mg,po,bid\*5; Weight>40kg,75mg,po,bid\*5.
Study NCT04183725 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oseltamivir phosphate granules
Description: Oseltamivir phosphate granules:~Weight≤15kg,30mg,po,bid\*5; 15\<Weight≤23kg,45mg,po,bid\*5; 23\<Weight≤40kg,60mg,po,bid\*5; Weight>40kg,75mg,po,bid\*5.~+Reduning injection simulants: 2≤Age≤5,0.5ml/kg/day,\<10ml/day+5％GS/0.9％NS 50～100ml,iv drip 30～40gtt/min qd\*5; 6≤Age≤10,10ml/day+5％GS/0.9％NS 100～200ml,iv drip 30～60gtt/min qd\*5; 11≤Age≤13,15ml/day+5％GS/0.9％NS 200～250ml,iv drip 30～60gtt/min qd\*5; Age=14,20ml/day+5％GS/0.9％NS 250ml,iv drip 30～60gtt/min qd\*5.
Study NCT01475344 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Human Fibrinogen Concentrate
Description: intravenous infusion over 5 min/vial:~Body Weight: \< 30 kg / 30-60 kg / 60 - 90 kg / > 90 kg~No. of vials: 1 vial (100 ml) / 2 vials (200 ml) / 3 vials (300 ml) / 4 vials (400 ml)~Fibrinogen Concentrate: 1.5 g / 3 g / 4.5 g / 6 g~Immediately after admission to hospital, the patient's parameters including blood collection (see below) will be measured for the second time (T2), if applicable, after the end of administration of the study drug. Additional measurements will be made 3 hours (T3), 9 hours (T4), and 24 hours (T5), 48 hours (T6) and one week after admission (T7). 30 days after inclusion in the study, a final investigation is planned (T8).
Study NCT01475344 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: intravenous infusion over 5 min/vial:~Body Weight: \< 30 kg / 30-60 kg / 60 - 90 kg / > 90 kg~No. of vials: 1 vial (100 ml) / 2 vials (200 ml) / 3 vials (300 ml) / 4 vials (400 ml)~Placebo: 1.5 g / 3 g / 4.5 g / 6 g~Immediately after admission to hospital, the patient's parameters including blood collection (see below) will be measured for the second time (T2), if applicable, after the end of administration of the study drug. Additional measurements will be made 3 hours (T3), 9 hours (T4), and 24 hours (T5), 48 hours (T6) and one week after admission (T7). 30 days after inclusion in the study, a final investigation is planned (T8).
Study NCT04961697 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hospital diaries
Description: Diaries will be used by family members, PICU staff or even the patient himself. They will take daily notes expressing feelings and thoughts and describing events that might help chronologically to better understand the course of disease and PICU stay. Photographs and other important PICU memories may also be used in the diary.
Study NCT03122392 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AMS 800
Description: AMS 800 Artificial Urinary Sphincter
Study NCT03810456 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Intensive Cognitive Behavior Therapy (iCBT)
Description: Participants randomized to iCBT will receive 16 hours of cognitive behavioral therapy for anxiety over one weekend. The treatment entails psychoeducation, cognitive restructuring and exposure exercises.
Study NCT03810456 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Cognitive Behavior Therapy (sCBT)
Description: Participants randomized to sCBT will receive 16 hours of cognitive behavioral therapy for anxiety weekly over a period of 12 weeks. The treatment entails psychoeducation, cognitive restructuring and exposure exercises.
Study NCT01296139 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferumoxytol
Description: All subjects will undergo pre-injection, 24, 48 hours post-Ferumoxytol injection (dose of 7.5mg/kg Fe) MRI consisting of T1 weighted (W), T2W and T2\*W MRI in a 3 Tesla magnet. Additionally, all subjects will undergo pre-injection, 24 hours, 48 hours post-Ferumoxytol injection (dose of 7.5mg/kg Fe) ultrasound.
Study NCT01599169 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary supplement : B-Back® (α-casozepine, taurine, eleutherococcus senticosus, Extramel)
Description: 2 tablets/day after breakfast during 12 weeks
Study NCT01599169 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: B-Back® placebo (without active compounds)
Description: 2 tablets/day after breakfast during 12 weeks
Study NCT00428480 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Daily reinforcement of walking speed (DRS)
Description: Inpatients are encouraged to walk faster and given feedback on their walking speed during a daily 10-meter walk as part of their usual physical therapy.
Study NCT00428480 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: No reinforcement of walking speed (NRS)
Description: Inpatients complete a 10-meter walk as part of their daily physical therapy but are not given any encouragement to walk faster or feedback on their walking speed.
Study NCT02798107 — intervention group
Intervention type: DRUG
Intervention: idarucizumab
Description: drug
Study NCT00433433 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABVD q4 weeks
Description: Doxorubicin 25 mg/m2 i.v. day 1 and 15; Bleomycin 10 mg/m2 i.v./i.m. day 1 and 15; Vinblastine 6 mg/m2 i.v. day 1 and 15; Dacarbazine 375 mg/m2 i.v. day 1 and 15
Study NCT00433433 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ABVD q4 weeks
Description: Doxorubicin 25 mg/m2 i.v. day 1 and 15; Bleomycin 10 mg/m2 i.v./i.m. day 1 and 15; Vinblastine 6 mg/m2 i.v. day 1 and 15; Dacarbazine 375 mg/m2 i.v. day 1 and 15
Study NCT00433433 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BEACOPP escalated q3 weeks
Description: Cyclophosphamide 1250 mg/m2 i.v. day 1; Doxorubicin 35 mg/m2 i.v. day 1; Vincristine 1.4 mg/m2 i.v.(max.2mg) day 8; Bleomycin 10 mg/m2 i.v./i.m. day 8; Etoposide 200 mg/m2/ i.v. day 1 to 3; Procarbazine 100 mg/m2 orally day 1 to 7; Prednisone 40 mg/m2 orally day 1 to 14; G-CSF 5 mcg/kg s.c. day 9 to recovery leukocytes>1.0x109/l
Study NCT00433433 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: IN-RT 30 Gy (+ boost 6 Gy residual)
Study NCT00433433 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: IN-RT 30 Gy (+ boost 6 Gy residual)
Study NCT00433433 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: FDG-PET scan
Study NCT00433433 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: FDG-PET scan
Study NCT03677869 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intraocular gas (C3F8)
Description: Intraocular gas (C3F8) injection
Study NCT00933504 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LACTIC ACID(ND)
Description: Treatment duration: 6 weeks.
Study NCT01844817 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OGX-427
Description: Three separate administrations of OGX-427 will be given during the 9-day Loading Dose Period. Following the Loading Dose Period, patients will receive 600mg OGX-427 prior to the administration of nab-paclitaxel (125mg/m2 IV)and gemcitabine (1000mg/m2 IV)administration on Day 1, 8, and 15 of each cycle. OGX-427 will also be administered on Day 22 during each cycle (i.e., weekly). Patients will continue 28 day treatment cycles until disease progression or until other reasons for discontinuation from treatment.
Study NCT01844817 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Three separate administrations of Placebo will be given during the 9-day Loading Dose Period. Following the Loading Dose Period, patients will receive placebo prior to the administration of nab-paclitaxel (125mg/m2 IV)and gemcitabine (1000mg/m2 IV)administration on Day 1, 8, and 15 of each cycle. Placebo will also be administered on Day 22 during each cycle (i.e., weekly). Patients will continue 28 day treatment cycles until disease progression or until other reasons for discontinuation from treatment.
Study NCT02759094 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Treatment with RefluxStop
Description: A standard laparoscopic approach will be used to reposition the lower oesophageal sphincter (LES) to its intra-abdominal position. The RefluxStop device will be then positioned and fixed in the gastric funds to ensure intra-abdominal positioning of the GEJ (Gastro-oesophageal Junction) at all time. After confirming proper placement, the laparoscopic implant procedure will be completed and access points will be closed.
Study NCT04851366 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PROCARE+ (with add-on modules)
Description: The modules will mainly consist in therapy sessions to provide the adolescents with tools to confront risk situations such as communication skills, coping skills to manage stress, etc. The group will include education about discussing thoughts, feelings, and behaviour as parts of emotion, and emphasis on providing support around the specific risks factors detected.
Study NCT04851366 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PROCARE (UP-A for selective purposes)
Description: This core intervention is meant to respond to the heterogeneity inherent in emotional difficulties presentation by extinguishing distress associated with the presentation of heightened negative emotion in general and reduction or elimination of resultant emotionally-driven behaviours, including avoidance, escape, aggression, and controlling behaviours (e.g., reassurance seeking) that reinforce emotional distress intensity over time.
Study NCT04851366 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active control condition
Description: Psychoeducation about many different emotions, emphasis on discussing thoughts, feelings, and behavior as parts of emotion, and emphasis on providing support around generally distressing events.
Study NCT04609423 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cod liver oil
Description: 5 ml of cod liver oil as a source of 10 ug of vitamin D and 1.2 g of long-chained n-3 polyunsaturated fatty acids (DHA 0,6g and EPA 0,4g) per day for 6 months x 1 time/day together with the first meal of the day. 5ml of Cod liver oil also contains 250ug vitamin A and 10 mg vitamin E.
Study NCT04609423 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Corn oil (placebo)
Description: 5 ml of corn oil per day for 6 months x 1 time/day together with the first meal of the day
Study NCT00832988 — intervention group
Intervention type: OTHER
Intervention: VentricularAutoCaptureTM & ACapTM Confirm
Description: The testing algorithms allow the device to display threshold measurements at time of device interrogation. These will be evaluated against manual testing results.
Study NCT01923675 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Spectacles with red-blocking tint
Description: Eyeglasses will have lenses that will correct refractive error for each subject, and will have a tint that blocks red light.
Study NCT01923675 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Spectacles with holographic diffuser and color neutral tint
Description: Eyeglasses will correct refractive error for each subject but will have a holographic diffuser applied to the surface and will have a color neutral filter to adjust the light intensity reaching the eyes to be the same as for groups 1 and3.
Study NCT01923675 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Spectacles with holographic diffuser and red-blocking tint
Description: Eyeglasses will correct refractive error for each subject and will be tinted to block red light, and will have a holographic diffuser to blur the image.
Study NCT01923675 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Spectacles with color neutral tint
Description: Eyeglasses will correct refractive error for each subject and will have a color neutral tint to adjust the light intensity reaching the eyes so it is the same as for groups 1 and 3.
Study NCT03214679 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Accessible Care
Description: Accessible Care will be provided by co-locating a hepatitis treatment provider, together with a Hepatitis C Care Coordinator, on-site at our collaborating needle exchange program.
Study NCT03214679 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Usual care entails referral to an on site HCV care coordinator (not provided by study)
Study NCT04617795 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Omnipod 5 Automated Insulin Delivery System
Description: The Omnipod 5 is a single hormone insulin delivery system intended for the management of diabetes in persons requiring insulin. Continuous subcutaneous insulin infusion may be delivered by user-defined settings (manual mode) or automatically adjusted in response to feedback from a continuous glucose monitor (CGM).~The Omnipod 5 can automatically increase insulin delivery based on sensor glucose values from the continuous glucose monitor (CGM) and can decrease or suspend delivery of insulin when the glucose value falls below or is predicted to fall below predefined threshold values.~The Omnipod 5 is designed to assist patients with diabetes in achieving glycemic targets set by their health care providers.
Study NCT00920777 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT
Description: Individual Cognitive Behavior Therapy during 16 weeks
Study NCT00920777 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT
Description: Individual Cognitive Behavior Therapy during 8 weeks
Study NCT00920777 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: Waiting 16 weeks and receiving 8 weeks individual CBT after waiting period.
Study NCT00181883 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: quetiapine
Description: 2.5 - 5.0mg/kg PO BID quetiapine
Study NCT01736735 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CLP
Study NCT01736735 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT00302536 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Tacrolimus
Study NCT03885323 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RF utilizing powered toothbrush
Description: RF utilizing Powered toothbrush
Study NCT03885323 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Control placebo with no RF
Description: Placebo control, with no RF
Study NCT04441788 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ION-827359
Description: ION-827359 administered by oral inhalation
Study NCT04441788 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered by oral inhalation
Study NCT04218721 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: InvolveMe
Description: An eHealth application that allows participants to report symptoms and needs prior to out-patient visits at the hospital. The application creates a summary that allows patients to prioritize what is important to talk with their health care providers about. Health care providers can use the summary to prepare the consultation.
Study NCT00829699 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: euinsulinemic euglycemic glucose clamp
Description: euinsulinemic euglycemic glucose clamp with lipid infusion 48 ml/hr for 4 hours
Study NCT00829699 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: euinsulinemic hyperglycemic glucose clamp
Description: euinsulinemic hyperglycemic glucose clamp with lipid infusion at 48 ml/hr for 4 hours
Study NCT00829699 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hyperinsulinemic euglycemic glucose clamp
Description: Hyperinsulinemic euglycemic glucose clamp with lipid infusion at 48 ml/hr for 4 hours
Study NCT00829699 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hyperinsulinemic hyperglycemic glucose clamp
Description: Hyperinsulinemic hyperglycemic glucose clamp with lipid infusion at 48 ml/hr for 4 hours
Study NCT00995722 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone will be adjusted based on combined measures of tolerability and efficacy. Capsules will contain 10mg of prednisone.
Study NCT00995722 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo dosages will be adjusted based on combined measures of tolerability and efficacy. Capsules will contain matching placebo.
Study NCT02945735 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Attention Modification
Description: Feedback according to participants' viewing patterns, in order to modify their attention.
Study NCT02945735 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Attention Modification
Description: Feedback according to participants' viewing patterns, in order to modify their attention.
Study NCT02052427 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Celution System
Description: ADRCs processed by the Celution System for reintroduction into the myocardium
Study NCT02052427 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Physiological solution made of Lactated Ringers solution and a small amount (\<1mL) of autologous blood
Study NCT00640939 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: diclofenac sodium
Description: 15 mg (1%) topical patch; measuring 7 cm by 10 cm; applied once daily
Study NCT00640939 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Description: Matching placebo patch, containing identical constituents to active patch except for diclofenac sodium; measuring 7 cm by 10 cm; applied once daily
Study NCT03604848 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: WHO-approved MDR-TB regimen
Description: Pyrazinamide 33-50kg 1000-1750 mg daily, 51-70kg 1750-2000 daily, >70kg 2000-2500mg daily; Amikacin 600mg daily ; Moxifloxacin 33-50kg 400 mg daily, 51-70kg 600mg daily, >70kg 800mg daily; Prothionamide 33-50kg 500 mg daily, 51-70kg 750 daily, >70kg 1000 mg daily ; Cycloserine 33-50kg 500 mg daily, 51-70kg 750 daily, >70kg 1000 mg daily All treatment is taken daily.
Study NCT03604848 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NGS-guided regimen: Regimen A
Description: Pyrazinamide 33-50kg 1000-1750 mg daily, 51-70kg 1750-2000 daily, >70kg 2000-2500mg daily; Amikacin 600mg daily ; Moxifloxacin 33-50kg 400 mg daily, 51-70kg 600mg daily, >70kg 800mg daily; Prothionamide 33-50kg 500 mg daily, 51-70kg 750 daily, >70kg 1000 mg daily ; Cycloserine 33-50kg 500 mg daily, 51-70kg 750 daily, >70kg 1000 mg daily All treatment is taken daily.
Study NCT03604848 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NGS-guided regimen: Regimen B
Description: Pyrazinamide 33-50kg 1000-1750 mg daily, 51-70kg 1750-2000 daily, >70kg 2000-2500mg daily; Amikacin 600mg daily ; Moxifloxacin 33-50kg 400 mg daily, 51-70kg 600mg daily, >70kg 800mg daily; Prothionamide 33-50kg 500 mg daily, 51-70kg 750 daily, >70kg 1000 mg daily ; Cycloserine 33-50kg 500 mg daily, 51-70kg 750 daily, >70kg 1000 mg daily All treatment is taken daily.
Study NCT03604848 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NGS-guided regimen: Regimen C
Description: Based on the drug susceptibility test results, the resistant drug(s) will be replaced by the other WHO recommended drugs for MDR-TB such as linezolid, clofazimine or ethambutol.~The dose of linezolid, clofazimine or ethambutol as follows:~Linezolid: 600 mg daily, clofazamine: 33-50kg 50 mg daily, 51-70kg 100 daily, >70kg 100 mg daily; ethambutol: 33-50kg 800 mg daily, 51-70kg 800 daily, >70kg 1200 mg daily;
Study NCT03957486 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: arterila cannulation on same arm
Description: arterila cannulation on same arm receiving continous hemoglobin monitoring
Study NCT03957486 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: arterila cannulation on different arm
Description: arterila cannulation different arm receiving continous hemoglobin monitoring
Study NCT02128659 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SHE Project
Description: Consists of five-sessions, starting on a Monday and ending Friday. Each day involves an approximately 2 hour session.
Study NCT06478511 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Classic Immediate implant
Description: The teeth will be extracted gently using periotomes to preserve facial and lingual bone plates. All walls of the socket will be inspected and checked for the presence of fenestration or dehiscence defects in bone. The length and width of extracted roots will be measured to determine the length and diameter of implants placed. The osteotomy sites will be prepared and the drills will be used in proper sequence according to manufacturer's instructions, with maximum use of bone apical to the extraction sockets. The drills will extend 3 to 5 mm beyond the apex of the socket to ensure primary stability after placement, taking care of the anatomical boundaries. The implants will be placed.
Study NCT06478511 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Immediate implant combined with subepithelial connective tissue graft
Description: Connective tissue graft was harvested from palate using trap door technique utilizing a horizontal incision 3-4 mm away from the gingival margin with two vertical incisions on the either end of the first incision, the door is then undermined and opened using a sharp dissection, the underlying connective tissue is then harvested using a periosteal elevator, and the door was then sutured using 4 0 silk sutures Finally, the connective tissue graft was immediately placed into the recipient site after a tunneling procedure and sutured with 6-0 nonresorbable monofilament sutures.